옵션 체인은 다양한 행사가격과 만기일에 대한 Mustang Bio의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Mustang Bio에 대한 시장 심리를 평가합니다..

Mustang Bio (NASDAQ:MBIO) 주식, 옵션 체인

Mustang Bio

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Equities

News

Markets

General

DKNG

MBIO

PLTR

TSLA

월요일, 미국 주요 지수는 상승세를 보였다. 다우존스 산업평균지수는 0.5% 가까이 오른 38,778.10에 마감했고, S&amp;P 500 지수는 0.8% 가까이 오른 5,473.23에, 나스닥 지수는 0.95% 상승한 17,857.02에 마감했다. 이들은 하루 동안 소매 거래자와 투자자들의 주목을 받은 인기 종목들이다:

월요일 주목받은 주식 5종목: 팔란티어, 머스탱 바이오, 드래프트킹스, 마이크론, 테슬라

Mustang Bio Inc

CERO

CERo Therapeutics Executes Agreement With Contract Research Organization CellCarta To Manage Translational Assays For Phase 1 Clinical Trial  Of CER-1236 In Acute Myeloid Leukemia

WIIM

Kodiak Gas Services shares are trading lower after the company reported worse-than-expected Q4 financial results.

B of A Securities analyst Bradley Sills maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Buy and lowers the price target from $420 to $286.

Price Target

Analyst Ratings

B of A Securities Maintains Buy on MongoDB, Lowers Price Target to $286

RGTI

Rigetti Computing shares are trading lower following a Q4 revenue miss.

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) with a Buy and raises the price target from $6 to $7.

OCGN

Chardan Capital Maintains Buy on Ocugen, Raises Price Target to $7

Contracts

KTOS

Naval Air Systems Command Awards Kratos Additional $59.3M For BQM-177A Subsonic Aerial Target Systems

Management

Masco Corporation CEO Keith Allman To Retire, Jonathon Nudi To Be Appointed PREsident And CEO Effective Jul. 7

B of A Securities analyst Vivek Arya maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Buy and lowers the price target from $150 to $120.

MRVL

B of A Securities Maintains Buy on Marvell Tech, Lowers Price Target to $120

Macro Economic Events

Global

Economics

ECB Cuts Deposit Facility Rate From 2.75% To 2.5%, Cuts Refi Rate From 2.9% To 2.65%

Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) shares are trading higher in the <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">premarket session on Thursday</a>.
The company reported fourth-quarter adjusted earnings per share of $4.13, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44161791/burlington-stores-inc-reports-fourth-quarter-and-full-year-2024-earnings" rel="noreferrer noopener">beating the street view of $3.76.</a>
Quarterly sales of $3.28 billion (+5% year over year) outpaced the analyst consensus estimate of $3.23 billion. Comparable store sales growth for the quarter was 6%, versus&nbsp;guidance&nbsp;of&nbsp;0%&nbsp;to&nbsp;2%.
&#8220;Taking 2024 as a whole, total sales increased 11%, comparable store sales increased 4%, and Adjusted EBIT Margin increased 100 basis points,&#8221; said Michael O&#8217;Sullivan, CEO.&nbsp;
The quarterly gross profit was $1.404 billion, up from $1.333 billion in the year-ago period. Gross margin expanded by 30 basis points to 42.9%, freight improved by 20 basis points, and merchandise margin increased by 10 basis points.
Adjusted EBITDA&nbsp;was $456 million in the quarter under review, higher than $412 million in the year-ago period.
Also Read:<a target="_blank" href="https://www.benzinga.com/news/large-cap/25/03/44161401/rio-tintos-1-8-billion-iron-ore-expansion-ramps-up-in-australia-details" rel="noreferrer noopener"> Rio Tinto&#8217;s $1.8 Billion Iron Ore Expansion Ramps Up In Australia: Details</a>
&#8220;We opened 101 net new stores in 2024 and relocated 31 of our older oversized locations,&#8221; the CEO added.
The company ended the fourth quarter with $1.822 billion in liquidity, comprised of $995 million in unrestricted cash.
Outlook: &#8220;The outlook for 2025 is very uncertain and we will plan and manage our business accordingly,&#8221; the CEO said.
The company expects total sales to increase by 6% &#8211; 8%, on top of the 11% increase the prior year. The company sees adjusted EPS of $8.70 &#8211; $9.30 (estimate: $9.43).
Burlington expects first-quarter total sales to increase 5% &#8211; 7%, comparable store sales are expected to be flattish. The company sees adjusted EPS of $1.30 &#8211; $1.45 (estimate: $1.68).
Price Action: BURL shares are trading higher by 12.5% to $266.50 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/forex/25/03/44161314/us-stocks-likely-to-open-lower-after-wednesdays-blip-be-patient-but-be-ready-to-act-says-analyst-as-market-uncertainties-can-create-opportunities" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Lower After Wednesday&#8217;s Blip: &#8216;Be Patient, But Be Ready To Act,&#8217; Says Analyst As Market Uncertainties Can Create &#8216;Opportunities&#8217;</a></li>
</ul>
Photo via Shutterstock.

Earnings

Guidance

Movers

BURL

Burlington Stock Jumps As Q4 Earnings Crush Estimates, But CEO Warns Of 'Uncertain' 2025 Outlook

RYAAY

Ryanair shares are trading lower after Morgan Stanley downgraded its rating on the stock from overweight to equal weight.

ADTX

Aditxt'ss Adimune Subsidiary To Ship Drug Substances For Final Drug Product Formulation Of ADI-100 Ahead Of Planned Trials For Type 1 Diabetes And Psoriasis In Germany And Stiff Person Syndrome At Mayo Clinic

B of A Securities analyst Peter Galbo maintains Campbell`s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) with a Underperform and lowers the price target from $45 to $41.

B of A Securities Maintains Underperform on Campbell's, Lowers Price Target to $41

Small Cap Consumer Research analyst Eric Beder reiterates Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) with a Buy and maintains $5.5 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on Vera Bradley, Maintains $5.5 Price Target

VRME

VerifyMe shares are trading lower after the company reported worse-than-expected Q4 earnings and sales.

MRAM

Everspin Awarded $10.5M Contract For MRAM IP And Foundry Services For Purdue University's ME Commons In-Memory Compute Project

Baird analyst Shrenik Kothari maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Outperform and raises the price target from $240 to $250.

Baird Maintains Outperform on Zscaler, Raises Price Target to $250

Earnings Beats

Earnings Misses

VYNE

VYNE Therapeutics Q4 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $84.000K Miss $140.000K Estimate

Baird analyst Joe Vruwink maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $283 to $285.

VEEV

Baird Maintains Outperform on Veeva Systems, Raises Price Target to $285

ALLR

Allarity Therapeutics Announces ITs Phase 2 Trial Of Stenoparib In Combination With Temozolomide For Recurrent Small Cell Lung Cancer, Being Fully Funded By US Veterans Administration

Financing

Press Releases

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Health Care

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Announces Reverse Stock Split

IPOs

Mustang Bio Announces Pricing of $8 Million Public Offering

Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

Aditxt

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Alzamend Neuro

Aptevo Therapeutics

180 Life Sciences

Azitra

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Carmell

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Galecto

GRI Bio

GT Biopharma

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Moleculin Biotech

Oragenics

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

SILO Pharma

Soligenix

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Theriva Biologics

Xenetic Biosciences

HC Wainwright & Co.

Cantor Fitzgerald

BTIG

Comments

Mustang Bio

Mustang Bio (MBIO) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌